Clinical Trial: Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease

U.S., Aug. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07147946) titled 'Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease' on Aug. 22.

Brief Summary: To evaluate the efficacy of TQC3721 Suspension for Inhalation in patients with moderate to severe Chronic obstructive pulmonary disease (COPD)

Study Start Date: Sept., 2025

Study Type: INTERVENTIONAL

Condition: Chronic Obstructive Pulmonary Disease

Intervention: DRUG: TQC3721 Suspension for inhalation

TQC3721 suspension for inhalation is a Phosphodiesterase3/4 (PDE3/4) inhibitor

DRUG: Placebo of TQC3721 Suspension for Inhalation

Placebo without drug substance

R...